How Much Did Stemcentrx Raise? Headquarters, Funding & Key Investors

Stemcentrx raised approximately $500M, including a $250M Series G in Aug 2015 backed by Fidelity, Founders Fund and Artis Ventures, and prior Series B and other rounds. Founded in 2008, Stemcentrx developed antibody-drug conjugates targeting cancer stem cells and companion diagnostics; multiple clinical candidates entered human trials with objective responses in several tumor types. Funding supported extensive R&D, IND filings, and early clinical development. The company was later acquired its scientific programs influenced oncology pipelines and partnerships in ADC development.

How Much Did Stemcentrx Raise? Funding & Key Investors

Stemcentrx focused on discovering and developing targeted therapeutics particularly ADCs directed at cancer stem cells and resistant tumor populations. Its platform combined biomarker discovery, antibody engineering, and potent payload chemistry to create targeted agents intended to deliver cytotoxic drugs selectively to tumor cells. Stemcentrx emphasized translational research and companion diagnostics to identify responsive patient subsets. Clinical signals in small cell lung cancer and other tumor types drew investor interest and strategic collaborations.

What Is Stemcentrx and What Does It Do?

Stemcentrx, founded in 2008 by Scott Dylla, is a San Francisco–based (United States) biopharma company focused on antibody-drug conjugates and cancer stem-cell biology. It employs 51-200 people and advanced multiple ADC candidates into clinical trials, developing companion diagnostics to match patients to therapy. The company’s approach aimed to improve therapeutic index and durability of responses by delivering highly potent payloads selectively to tumor cells.

How Much Funding Has Stemcentrx Raised?

1. Series G

Amount Raised: $250M
Date: Aug 2015
Lead Investors: Fidelity Investments, Founders Fund, Artis Ventures
Motivation: Support late preclinical and early clinical development, IND filings, and translational programs.

2. Series B (earlier)

Amount Raised: $23.5M
Date: Mar 16, 2011
Motivation: Advance lead programs into IND and Phase I testing.

Total Funding Raised: $500M

Latest Funding Date: Aug 2015

Key Investors

1. Fidelity Investments

Details: Large institutional investor backing biotech and healthcare growth companies.
Investment Focus Areas: Biopharma, healthcare services, biotech R&D.
Notable Investments: Moderna, Illumina, Alnylam, Stemcentrx.

2. Founders Fund

Details: Venture firm investing across deep tech and biotech.
Investment Focus Areas: Deep science, biotech, defense, AI.
Notable Investments: SpaceX, Palantir, Stemcentrx, Stripe.

3. Artis Ventures

Details: Early-stage investor focused on technology and life sciences.
Investment Focus Areas: Biotech, diagnostics, platform technologies.
Notable Investments: Stemcentrx, MyoKardia, AgBiome.

Where Is Stemcentrx’s Headquarters?

Stemcentrx is headquartered in San Francisco, California, close to major biotech research institutions and clinical partners.

What’s Next for Stemcentrx?

Following strategic transactions, Stemcentrx’s scientific assets continue via partners or acquirers; next steps typically involve partnering programs, further clinical development, and companion diagnostic validation to match patients to ADC therapies.

Get Investor & Funding Insights with TexAu

TexAu helps sales and business teams uncover detailed fundraising information on companies like Stemcentrx. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.

Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.